Álvaro Vega-Hidalgo

Álvaro Vega-Hidalgo

Auto-generated profile, based on publicly available information

Álvaro Vega-Hidalgo

Weber Foundation, Madrid, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Apidologie
Verified
Journal Article
Closed access
PDF file
ÁVÁlvaro Vega-Hidalgo
Álvaro Vega-Hidalgo
YAYostin Añino
Yostin Añino
EKErin Krichilsky
Erin Krichilsky
ASAdam R. Smith
Adam R. Smith
ASAlonso Santos-Murgas
Alonso Santos-Murgas
DGDumas Gálvez
Dumas Gálvez

24 April 2022 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
NZNéboa Zozaya
Néboa Zozaya
FAFernando Abdalla
Fernando Abdalla
SZSantiago Alfonso Zamora
Santiago Alfonso Zamora
JFJesús Balea Filgueiras
Jesús Balea Filgueiras
José Manuel CarrascosaJosé Manuel Carrascosa
José Manuel Carrascosa
ÁHÁlvaro Hidalgo-Vega
Álvaro Hidalgo-Vega
Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.

27 February 2020 in Journal of Hymenoptera Research
Verified
Journal Article
Open access
PDF file
EKErin Krichilsky
Erin Krichilsky
ÁVÁlvaro Vega-Hidalgo
Álvaro Vega-Hidalgo
KHKate Hunter
Kate Hunter
CKCallum Kingwell
Callum Kingwell
CRChelsey Ritner
Chelsey Ritner
ASAdam Smith
Adam Smith
Gynandromorphy is an anomaly that results in an organism phenotypically expressing both male and female characteristics. Here we describe the first gynandromorph of the bee species Megalopta amoena (Spinola, 1853) (Halictidae, Augochlorini) and the second record of this anomaly within the genus Megalopta. Additionally, we analyzed the bee’s circadian rhythm, which has never before been quantified for a gynandromorph. The gynandromorph showed a deviant activity pattern; it was intermediate between that of the male and female M. amoena. Our results imply that the brains of bilateral gynandromorphs may have mixed sex-specific signaling. Based on four days of recording, the gynandromorph circadian rhythm was shifted earlier in the day relative to the male and female M. amoena, and it exhibited intensity similar to the female.

26 February 2019 in UNED Research Journal
Verified
Journal Article
Open access
PDF file
JGJosé Pablo Barquero González
José Pablo Barquero González
AVAlvaro Vega-Hidalgo
Alvaro Vega-Hidalgo
JMJulián Monge-Nájera
Julián Monge-Nájera
We report, for the first time in onychophorans, food hiding, parental feeding investment and an ontogenetic diet shift two weeks after birth: from the parent’s adhesive used to capture prey, to the prey itself.

3 April 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
NZNéboa Zozaya
Néboa Zozaya
BRB. Alcalá Revilla
B. Alcalá Revilla
PMP. Arrazola Martínez
P. Arrazola Martínez
JBJ. R. Chávarri Bravo
J. R. Chávarri Bravo
IEI. Cuesta Esteve
I. Cuesta Esteve
AHA. Hidalgo-Vega
A. Hidalgo-Vega
Objective: To advance the development of an ideal and sustainable framework agreement for the public procurement of vaccines in Spain, and to agree on the desirable award criteria and their relative weight. Methods: A multidisciplinary committee of seven health-care professionals and managers developed a partial multi-criteria decision analysis to determine the award criteria that should be considered and their specific weights for the public procurement of routine vaccines and seasonal influenza vaccines, considering their legal viability. A re-test of the results was carried out. The current situation was analyzed through 118 tender specifications and compared to the ideal framework. Results: Price is the prevailing award criterion for the public procurement of both routine (weighting of 60% versus 40% for all other criteria) and influenza (36% versus 64%) vaccines. Ideally, 22 criteria should be considered for routine vaccines, grouped and weighted into five domains: efficacy (weighting of 29%), economic aspects (27%), vaccine characteristics (22%), presentation form and packaging (13%), and others (9%). Per criteria set, price was the most important criterion (22%), followed by effectiveness (9%), and composition/formulation (7%). Regarding influenza vaccines, 20 criteria were selected, grouped, and weighted: efficacy (29%), economic aspects (25%), vaccine characteristics (20%), presentation form and packaging (16%), and others (11%). Per criteria set, price was also the most relevant criterion (19%), followed by composition/formulation (8%), and effectiveness (8%). Conclusions: Contrary to the current approach, technical award criteria should prevail over economic criteria in an ideal and sustainable framework agreement for the public procurement of vaccines.